Marina Naldi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9320816/publications.pdf

Version: 2024-02-01

304743 361022 1,376 62 22 35 citations h-index g-index papers 62 62 62 2439 citing authors all docs docs citations times ranked

#	Article	IF	CITATIONS
1	HSA-Binding Prodrugs-Based Nanoparticles Endowed with Chemo and Photo-Toxicity against Breast Cancer. Cancers, 2022, 14, 877.	3.7	7
2	Discovery and In Vivo Proof of Concept of a Highly Potent Dual Inhibitor of Soluble Epoxide Hydrolase and Acetylcholinesterase for the Treatment of Alzheimer's Disease. Journal of Medicinal Chemistry, 2022, 65, 4909-4925.	6.4	22
3	Discovery of sustainable drugs for Alzheimer's disease: cardanol-derived cholinesterase inhibitors with antioxidant and anti-amyloid properties. RSC Medicinal Chemistry, 2021, 12, 1154-1163.	3.9	11
4	Discovery of an Allosteric Ligand Binding Site in SMYD3 Lysine Methyltransferase. ChemBioChem, 2021, 22, 1597-1608.	2.6	8
5	From Combinations to Single-Molecule Polypharmacologyâ€"Cromolyn-Ibuprofen Conjugates for Alzheimer's Disease. Molecules, 2021, 26, 1112.	3.8	6
6	Determination of Effective Albumin in Patients With Decompensated Cirrhosis: Clinical and Prognostic Implications. Hepatology, 2021, 74, 2058-2073.	7.3	45
7	New Coumarin Derivatives as Cholinergic and Cannabinoid System Modulators. Molecules, 2021, 26, 3254.	3.8	8
8	Bio-Guided Fractionation of Stem Bark Extracts from Phyllanthus muellarianus: Identification of Phytocomponents with Anti-Cholinesterase Activity. Molecules, 2021, 26, 4376.	3.8	2
9	From virtual screening hits targeting a cryptic pocket in BACE-1 to a nontoxic brain permeable multitarget anti-Alzheimer lead with disease-modifying and cognition-enhancing effects. European Journal of Medicinal Chemistry, 2021, 225, 113779.	5.5	7
10	Advanced analytical methodologies in Alzheimer's disease drug discovery. Journal of Pharmaceutical and Biomedical Analysis, 2020, 178, 112899.	2.8	17
11	In vitro thrombogenicity of drug-eluting and bare metal stents. Thrombosis Research, 2020, 185, 43-48.	1.7	5
12	Indole Derivative Interacts with Estrogen Receptor Beta and Inhibits Human Ovarian Cancer Cell Growth. Molecules, 2020, 25, 4438.	3.8	7
13	Effective albumin concentration and albumin function improve after long-term albumin treatment in patients with decompensated cirrhosis. Journal of Hepatology, 2020, 73, S211-S212.	3.7	O
14	Unveiling the molecular mechanisms underpinning biorecognition of early-glycated human serum albumin and receptor for advanced glycation end products. Analytical and Bioanalytical Chemistry, 2020, 412, 4245-4259.	3.7	7
15	Functional characterization of multifunctional ligands targeting acetylcholinesterase and alpha 7 nicotinic acetylcholine receptor. Biochemical Pharmacology, 2020, 177, 114010.	4.4	6
16	Unveiling the Biochemistry of the Epigenetic Regulator SMYD3. Biochemistry, 2019, 58, 3634-3645.	2.5	8
17	Investigating in Vitro Amyloid Peptide 1–42 Aggregation: Impact of Higher Molecular Weight Stable Adducts. ACS Omega, 2019, 4, 12308-12318.	3.5	19
18	Tacrine-O-protected phenolics heterodimers as multitarget-directed ligands against Alzheimer's disease: Selective subnanomolar BuChE inhibitors. European Journal of Medicinal Chemistry, 2019, 181, 111550.	5.5	21

#	Article	IF	CITATIONS
19	Dual-Acting Cholinesterase–Human Cannabinoid Receptor 2 Ligands Show Pronounced Neuroprotection in Vitro and Overadditive and Disease-Modifying Neuroprotective Effects in Vivo. Journal of Medicinal Chemistry, 2019, 62, 9078-9102.	6.4	35
20	Discovery of novel benzofuran-based compounds with neuroprotective and immunomodulatory properties for Alzheimer's disease treatment. European Journal of Medicinal Chemistry, 2019, 178, 243-258.	5 . 5	32
21	PS-102-Circulating native albumin in patients with cirrhosis admitted to hospital for acute decompensation and acute-on-chronic liver failure: Relation to serum albumin levels, albumin function, and patient outcomes. Journal of Hepatology, 2019, 70, e65.	3.7	0
22	Polycyclic Maleimide-based Scaffold as New Privileged Structure for Navigating the Cannabinoid System Opportunities. ACS Medicinal Chemistry Letters, 2019, 10, 596-600.	2.8	6
23	Design, biological evaluation and X-ray crystallography of nanomolar multifunctional ligands targeting simultaneously acetylcholinesterase and glycogen synthase kinase-3. European Journal of Medicinal Chemistry, 2019, 168, 58-77.	5 . 5	51
24	New insights into the altered binding capacity of pharmaceutical-grade human serum albumin: site-specific binding studies by induced circular dichroism spectroscopy. Journal of Pharmaceutical and Biomedical Analysis, 2019, 162, 171-178.	2.8	20
25	Immobilized Enzyme Reactors: an Overview of Applications in Drug Discovery from 2008 to 2018. Chromatographia, 2019, 82, 425-441.	1.3	27
26	A patent review of butyrylcholinesterase inhibitors and reactivators 2010–2017. Expert Opinion on Therapeutic Patents, 2018, 28, 455-465.	5.0	31
27	Isolation and Characterization of Wheat Derived Nonspecific Lipid Transfer Protein 2 (nsLTP2). Journal of Food Science, 2018, 83, 1516-1521.	3.1	6
28	Exploiting the Chalcone Scaffold to Develop Multifunctional Agents for Alzheimer's Disease. Molecules, 2018, 23, 1902.	3.8	22
29	Immobilized enzyme-based analytical tools in the -omics era: Recent advances. Journal of Pharmaceutical and Biomedical Analysis, 2018, 160, 222-237.	2.8	23
30	Towards automation in protein digestion: Development of a monolithic trypsin immobilized reactor for highly efficient on-line digestion and analysis. Talanta, 2017, 167, 143-157.	5 . 5	41
31	Application of an ESI-QTOF method for the detailed characterization of GSK- $3\hat{l}^2$ inhibitors. Journal of Pharmaceutical and Biomedical Analysis, 2017, 144, 159-166.	2.8	7
32	Structural and functional integrity of human serum albumin: Analytical approaches and clinical relevance in patients with liver cirrhosis. Journal of Pharmaceutical and Biomedical Analysis, 2017, 144, 138-153.	2.8	43
33	Quinazoline based $\hat{l}\pm 1$ -adrenoreceptor antagonists with potent antiproliferative activity in human prostate cancer cell lines. European Journal of Medicinal Chemistry, 2017, 136, 259-269.	5. 5	11
34	Simple and rapid LCâ€"MS method for the determination of circulating albumin microheterogeneity in veal calves exposed to heat stress. Journal of Pharmaceutical and Biomedical Analysis, 2017, 144, 263-268.	2.8	4
35	Structural basis for the magnesium-dependent activation of transketolase from Chlamydomonas reinhardtii. Biochimica Et Biophysica Acta - General Subjects, 2017, 1861, 2132-2145.	2.4	11
36	Albumin Homodimers in Patients with Cirrhosis: Clinical and Prognostic Relevance of a Novel Identified Structural Alteration of the Molecule. Scientific Reports, 2016, 6, 35987.	3.3	35

3

#	Article	IF	CITATIONS
37	Mass spectrometry characterization of circulating human serum albumin microheterogeneity in patients with alcoholic hepatitis. Journal of Pharmaceutical and Biomedical Analysis, 2016, 122, 141-147.	2.8	16
38	Direct determination of GSK- $3\hat{l}^2$ activity and inhibition by UHPLC-UVâ \in vis diode arrays detector (DAD). Journal of Pharmaceutical and Biomedical Analysis, 2016, 124, 104-111.	2.8	2
39	Synthesis, cytotoxicity and anti-cancer activity of new alkynyl-gold(<scp>i</scp>) complexes. Dalton Transactions, 2016, 45, 1546-1553.	3.3	29
40	Ischaemiaâ€modified albumin: a marker of bacterial infection in hospitalized patients with cirrhosis. Liver International, 2015, 35, 2425-2432.	3.9	20
41	Mass spectrometric characterization of human serum albumin dimer: A new potential biomarker in chronic liver diseases. Journal of Pharmaceutical and Biomedical Analysis, 2015, 112, 169-175.	2.8	29
42	Posttranscriptional changes of serum albumin: Clinical and prognostic significance in hospitalized patients with cirrhosis. Hepatology, 2014, 60, 1851-1860.	7.3	135
43	UHPLC determination of catechins for the quality control of green tea. Journal of Pharmaceutical and Biomedical Analysis, 2014, 88, 307-314.	2.8	50
44	Fluorescence biosensing micropatterned surfaces based on immobilized human acetylcholinesterase. Analytical and Bioanalytical Chemistry, 2013, 405, 795-804.	3.7	3
45	Amyloid β-Peptide 25–35 Self-Assembly and Its Inhibition: A Model Undecapeptide System to Gain Atomistic and Secondary Structure Details of the Alzheimer's Disease Process and Treatment. ACS Chemical Neuroscience, 2012, 3, 952-962.	3.5	85
46	Mechanism and stereoselectivity of HDAC I inhibition by (R)-9-hydroxystearic acid in colon cancer. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2012, 1821, 1334-1340.	2.4	30
47	Disclosure of a fundamental clue for the elucidation of the myricetin mechanism of action as amyloid aggregation inhibitor by mass spectrometry. Electrophoresis, 2012, 33, 3380-3386.	2.4	17
48	Kinetic characterization of amyloid-beta $1\hat{a}\in$ "42 aggregation with a multimethodological approach. Analytical Biochemistry, 2011, 414, 215-225.	2.4	103
49	AFM study of F-actin on chemically modified surfaces. , 2010, , .		0
50	HS–SPME–GC–MS for the Quantitation and Chiral Characterization of Camphor and Menthol in Creams. Chromatographia, 2010, 72, 941-947.	1.3	16
51	Structural characterization of p53 isoforms due to the polymorphism at codon 72 by mass spectrometry and circular dichroism. Journal of Pharmaceutical and Biomedical Analysis, 2010, 53, 200-206.	2.8	3
52	Characterisation of the conjugate of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin with lactosaminated human albumin by 13C NMR spectroscopy. European Journal of Pharmaceutical Sciences, 2009, 38, 262-269.	4.0	13
53	Histone postâ€translational modifications by HPLCâ€ESIâ€MS after HT29 cell treatment with histone deacetylase inhibitors. Proteomics, 2009, 9, 5437-5445.	2.2	25
54	Self-assembly of biomolecules: AFM study of F-actin on unstructured and nanostructured surfaces. , 2009, , .		1

#	Article	IF	CITATION
55	Analysis of human histone H4 by capillary electrophoresis in a pullulan-coated capillary, LC-ESI-MS and MALDI-TOF-MS. Analytical and Bioanalytical Chemistry, 2008, 390, 1881-1888.	3.7	12
56	Rapid MALDI-TOF-MS analysis in the study of interaction between whole bacterial cells and human target molecules: Binding of Bifidobacterium to human plasminogen. Journal of Microbiological Methods, 2008, 73, 276-278.	1.6	4
57	Bright OligothiopheneN-Succinimidyl Esters for Efficient Fluorescent Labeling of Proteins and Oligonucleotides. Bioconjugate Chemistry, 2007, 18, 1015-1015.	3 . 6	0
58	Development and characterization of \hat{l}^2 -secretase monolithic micro-immobilized enzyme reactor for on-line high-performance liquid chromatography studies. Journal of Chromatography A, 2007, 1175, 217-226.	3.7	30
59	Multiwell fluorometric and colorimetric microassays for the evaluation of beta-secretase (BACE-1) inhibitors. Analytical and Bioanalytical Chemistry, 2007, 388, 1175-1183.	3.7	47
60	Bright OligothiopheneN-Succinimidyl Esters for Efficient Fluorescent Labeling of Proteins and Oligonucleotides. Bioconjugate Chemistry, 2006, 17, 58-67.	3.6	55
61	Histone proteins determined in a human colon cancer by high-performance liquid chromatography and mass spectrometry. Journal of Chromatography A, 2006, 1129, 73-81.	3.7	25
62	Oligothiophene phosphoramidites for oligonucleotide labelling. Tetrahedron Letters, 2005, 46, 8181-8184.	1.4	15